Supreme Court Refuses Delay on Copaxone Competition
The U.S. Supreme Court has ruled against a Teva Pharmaceutical Industries motion to delay marketing of generic competition for its lucrative multiple sclerosis drug Copaxone, Globes reported on Thursday.
Chief Justice John Roberts rejected Teva’s request to put a lower-court ruling on hold while it decides on the appeal that Teva has submitted. The lower court determined that Teva’s Copaxone patent would expire May 2014 rather than September 2015.
Pharmaceutical companies seeking to market a rival generic treatment to Copaxone said that generic alternatives will aid multiple sclerosis patients. At present, annual use of Copaxone in the U.S. can cost $40,000.
Copaxone has annual sales of over $4 billion worldwide, including $2.2 billion sales in the U.S.
This article appeared in print on page 8 of edition of Hamodia.
To Read The Full Story
Are you already a subscriber?
Click "Sign In" to log in!
Become a Web Subscriber
Click “Subscribe” below to begin the process of becoming a new subscriber.
Become a Print + Web Subscriber
Click “Subscribe” below to begin the process of becoming a new subscriber.
Renew Print + Web Subscription
Click “Renew Subscription” below to begin the process of renewing your subscription.
